Updated:
Vicore Pharma Holding AB
Vicore Pharma Holding AB is a Swedish biotech firm developing C21 for pulmonary fibrosis, led by CEO Jan Nilsson. Publicly traded on Nasdaq Stockholm.
Vicore Pharma Holding AB
Vicore Pharma Holding AB was founded in 2001 to develop treatments for rare lung diseases, with CEO Jan Nilsson and Chairman Carl-Johan Dalsgaard. The company's primary asset is C21, an angiotensin II type 2 receptor agonist for idiopathic pulmonary fibrosis. The firm pursues a single-asset strategy, developed C21 through Phase 1 and Phase 2a trials. Vicore has raised capital via rights issues and public funding, including 150 million SEK in a 2023 rights offering. The drug targets fibrosis, a condition with high unmet need, but has not yet reached late-stage trials. The company has a team of 15-20 professionals based in Gothenburg. Vicore is publicly traded on the Nasdaq Stockholm First North Growth Market. As of 2025, the firm had cash reserves of 200 million SEK, per its Q1 2025 report. Vicore's structural differentiator is its focused pipeline on a single, novel pathway for fibrosis, which reduces operational complexity but concentrates risk. The company relies on partnerships for late-stage development rather than building a broad portfolio.
General information
Firm type
Biotechnology firm
Year founded
2001
AUM
Undisclosed (Altss estimate)
Location
Region
Europe
Country
Sweden
City
Gothenburg
Corporate office
Gothenburg, Sweden
Principals
Jan Nilsson
CEO
Carl-Johan Dalsgaard
Chairman
Sector focus
Frequently asked questions
What is Vicore Pharma's primary drug candidate?
Vicore's lead asset is C21, an angiotensin II type 2 receptor agonist for idiopathic pulmonary fibrosis. It has completed Phase 2a trials as of 2024. The drug is not yet approved.
Who leads Vicore Pharma?
Jan Nilsson serves as CEO. Carl-Johan Dalsgaard is Chairman. Both have backgrounds in Swedish pharma.
How is Vicore Pharma funded?
Vicore raises capital through equity offerings, including a 150 million SEK rights issue in 2023. It holds cash reserves of approximately 200 million SEK as of Q1 2025.
What stage of clinical development is C21 in?
C21 completed a Phase 2a trial in IPF patients, with positive top-line results announced in May 2024. No Phase 3 trial has yet been initiated.
Does Vicore Pharma have a partnership for C21?
No disclosed late-stage partnership. Vicore operates independently for early development, per public filings.
Where is Vicore Pharma headquartered?
The company is based in Gothenburg, Sweden, with no other disclosed offices.
What is the regulatory status of Vicore's stock?
Vicore is listed on Nasdaq Stockholm First North Growth Market, a junior exchange for smaller companies.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: